BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, November 5, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» PAR4 antagonist demonstrates robust antithrombotic efficacy in vivo
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hematologic
PAR4 antagonist demonstrates robust antithrombotic efficacy in vivo
April 12, 2024
No Comments
Researchers from Bristol Myers Squibb Co. have published details on the discovery and characterization of novel protease-activated receptor 4 (PAR4) antagonists as potential antiplatelet therapy candidates.
BioWorld Science
Hematologic